secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001558370-24-016089
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx granted FDA RMAT designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia
--------------------------------------------------------------------------------

- FDA's RMAT designation includes Fast Track, Breakthrough Therapy benefits and potential Priority Review and accelerated approval.
- Phase 1 AQUAx trial showed significant patient-reported outcomes and saliva production improvements with no serious adverse events.
- Phase 2 AQUAx2 double-blind, placebo-controlled trial is enrolling; FDA agreed Phase 2 may serve as pivotal trial for BLA filing.
- AAV2-hAQP1 previously received FDA Orphan Drug Designation for this indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024016089/0001558370-24-016089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024016089/mgtx-20241209x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer